everolimus

FDA Drug Profile — Zortress, EVEROLIMUS, everolimus, Everolimus, Afinitor Disperz

everolimus is listed in the FDA National Drug Code directory with 63 NDC codes, marketed under brand names including Zortress, EVEROLIMUS, everolimus. Available dosage forms: tablet, tablet, for suspension, powder.

Drug details

Generic Name
everolimus
Brand Names
Zortress, EVEROLIMUS, everolimus, Everolimus, Afinitor Disperz, Afinitor
Application Number
NDA021560
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
63
Dosage Forms
TABLET, TABLET, FOR SUSPENSION, POWDER
Routes
ORAL
Active Ingredients
EVEROLIMUS

Indications and Usage

1 INDICATIONS AND USAGE Everolimus is a kinase inhibitor indicated for the treatment of: • Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) • Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) 1.3 Renal Cell Carcinoma (RCC) Everolimus is indicated for the treatment of adult patients with advanced RCC after failure of treatment with sunitinib or sorafenib. 1.4 Tuberous Sclerosis Complex (TSC)-Associated Renal Angiomyolipoma Everolimus is indicated for the treatment of adult patients with renal angiomyolipoma and TSC, not requiring immediate surgery.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.